AIMS: The aim of this study was to report circulating cell-free DNA using ALU247 and ALU247/ALU115 biomarkers in serum of operated and non-operated patients with colorectal cancer (CRC). METHODS: To undertake this, 90 blood samples were collected, including 30 samples from healthy volunteers; 27 samples from CRC non-operated patients and 33 samples from CRC-operated patients. Circulating cell-free DNA was verified through quantitative real-time PCR (qPCR) using ALU115 and ALU247 primers. RESULTS: With regard to the ALU115-qPCR biomarker, the increased levels of circulating cell-free DNA in serum of non-operated patients were significant when compared with control (p<0.05). Moreover, levels of ALU247-qPCR biomarker were statistically significant between non-operated versus operated and non-operated versus control groups (p=0.000). With regard to the ALU247/115-qPCR biomarker, significant differences were observed between control versus non-operated patients (p=0.019), operated versus non-operated patients (p=0.005) and control versus operated patients (p=0.043). CONCLUSIONS: Thus, the ALU247 and ALU247/ALU115-qPCR biomarkers may be important in detecting and monitoring CRC patients in both early and late stages.
AIMS: The aim of this study was to report circulating cell-free DNA using ALU247 and ALU247/ALU115 biomarkers in serum of operated and non-operated patients with colorectal cancer (CRC). METHODS: To undertake this, 90 blood samples were collected, including 30 samples from healthy volunteers; 27 samples from CRC non-operated patients and 33 samples from CRC-operated patients. Circulating cell-free DNA was verified through quantitative real-time PCR (qPCR) using ALU115 and ALU247 primers. RESULTS: With regard to the ALU115-qPCR biomarker, the increased levels of circulating cell-free DNA in serum of non-operated patients were significant when compared with control (p<0.05). Moreover, levels of ALU247-qPCR biomarker were statistically significant between non-operated versus operated and non-operated versus control groups (p=0.000). With regard to the ALU247/115-qPCR biomarker, significant differences were observed between control versus non-operated patients (p=0.019), operated versus non-operated patients (p=0.005) and control versus operated patients (p=0.043). CONCLUSIONS: Thus, the ALU247 and ALU247/ALU115-qPCR biomarkers may be important in detecting and monitoring CRC patients in both early and late stages.
Authors: Wesley K Utomo; Vincent T Janmaat; Auke P Verhaar; Jérôme Cros; Philippe Lévy; Philippe Ruszniewski; Mirella S Vredenbregt-van den Berg; Guido Jenster; Marco J Bruno; Henri Braat; Gwenny M Fuhler; Maikel P Peppelenbosch Journal: Am J Cancer Res Date: 2016-08-01 Impact factor: 6.166
Authors: Zijian Yang; Michael J LaRiviere; Jina Ko; Jacob E Till; Theresa Christensen; Stephanie S Yee; Taylor A Black; Kyle Tien; Andrew Lin; Hanfei Shen; Neha Bhagwat; Daniel Herman; Andrew Adallah; Mark H O'Hara; Charles M Vollmer; Bryson W Katona; Ben Z Stanger; David Issadore; Erica L Carpenter Journal: Clin Cancer Res Date: 2020-04-16 Impact factor: 12.531
Authors: Michail Galanopoulos; Nikolaos Tsoukalas; Ioannis S Papanikolaou; Maria Tolia; Maria Gazouli; Gerassimos J Mantzaris Journal: World J Gastrointest Oncol Date: 2017-04-15